Navigation Links
New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
Date:11/10/2007

Data Also Showed That Over a 6 Month Period, Nasacort AQ Did Not Cause

Significant Adrenal Suppression in This Same Age Group

BRIDGEWATER, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Data presented at the American College of Allergy, Asthma & Immunology (ACAAI) annual meeting suggests that the intranasal corticosteroid Nasacort AQ (triamcinolone acetonide) Nasal Spray may be used safely and effectively to treat children aged 2-5 years old with year-round allergic rhinitis. The same study also showed that during the study, Nasacort AQ did not show a significant effect on adrenal function among a subset of the same patients.

Caused by an allergic reaction to allergens such as house dust, animal dander, or pollen, allergic rhinitis is the most common chronic childhood disease, effecting as many as 40% of all children in the U.S.

A clinical study suggests that Nasacort AQ may present a safe and effective treatment option in children aged 2-5 years with year-round allergic rhinitis

In a multicenter, randomized, double-blind study, Nasacort AQ, given as 1 spray per nostril once daily for 4 weeks, improved combined symptoms of sneezing, nasal itching, discharge, and congestion, compared with placebo in children aged 2-5 years who have had year-round allergic rhinitis for at least one year. Nasacort AQ also showed comparable safety to placebo.

"This study suggests that Nasacort AQ may be used safely and effectively to treat young children who suffer from year-round allergies," said lead investigator Dr. Steven Weinstein of University of California at Irvine College of Medicine.

This study is the first and only randomized, double-blind, placebo-controlled study designed specifically to investigate both the efficacy and safety of an intranasal corticosteroid in this very young age group. A total of 474 patients were randomized to receive either Nasacort AQ or placebo as 1 spray per nostril once daily for 4 weeks. To participate in the study, patients had to have year-round allergic rhinitis for at least one year and reported sufficiently severe symptoms of nasal stuffiness, discharge and sneezing. Also, all patients had to demonstrate sensitivity to such allergens in their system as shown by a positive skin prick test.

Every morning, caregivers were asked to rate his/her child's symptoms of sneezing, nasal stuffiness, discharge, and itching over the last 24 hours (reflective). Patients' symptoms were also rated at the time immediately before receiving their daily medication (instantaneous).

Over four weeks, patients treated with Nasacort AQ showed a statistically significant (P=0.0328) reduction in the combined symptoms of sneezing, nasal stuffiness, discharge and itching (Total Symptom Score or TSS) measured over the last 24 (-2.31 plus or minus 0.15) compared to placebo (-1.87 plus or minus .151). Immediately before receiving the daily treatment, patients treated with Nasacort AQ also reported a numeric, albeit not statistically significant (P= 0.0946), reduction (-2.28 plus or minus 0.16) in TSS compared to placebo (-1.92 plus or minus .16).

Side effects among patients treated with Nasacort AQ were similar to those given placebo and no serious adverse events or clinically meaningful changes in vital signs were reported in either group. Side effects associated with treatment occurred in 50.8% of patients receiving Nasacort AQ and 48.3% of subjects receiving placebo. The most common treatment-related adverse events during the 4-week of treatment with Nasacort AQ and placebo respectively were cough (7.6%, 9.2%), pyrexia (fever) (6.8%, 8%), headache (5.5%, 4.2%), and nasopharyngitis (nose & throat irritation) (5.1%, 3.8%).

In a subset of the same clinical study, Nasacort AQ showed no significant effect on average adrenal function in children aged 2-5 years with year-round allergic rhinitis

Also presented at ACAAI is a report on the effect of Nasacort AQ on adrenal function from a subset of patients who participated in the same study described above. Adrenal function is responsible for many body processes such as response to stress, metabolism, the immune system, and sexual development and function.

Results reported by Dr. Nayak showed that 4 weeks of Nasacort AQ, given as 1 spray in each nostril once daily, did not significantly affect the average blood levels of the adrenal hormone "cortisol" compared with placebo among children 2-5 years with year-round allergic rhinitis.

"Traditionally there has been a concern regarding potential effects of the widely-used intranasal corticosteroids on adrenal function in children," said lead investigator Dr. Anjuli Nayak, University of Illinois College of Medicine. "We are encouraged by the results of this study which showed that during the 6 month study, Nasacort AQ did not cause significant adrenal suppression in children aged 2-5 years who suffer from year-round allergies."

Adrenal function was assessed in a subset of 61 children aged 2-5 years with PAR who received Nasacort AQ (n=33) or placebo (n=28) in the 4-week double-blind treatment phase; and in a subset of 49 children who continued on in a 6-month long open label extension period receiving Nasacort AQ once daily. To participate, patients had year-round allergic rhinitis for one year or longer and a positive skin prick test for allergens. Also, upon entering the study, patients needed normal morning cortisol levels. Cortisol measurements were conducted before and after adrenal stimulation with 1 mcg of cosyntropin hormone. A reduction in cortisol levels while receiving an intranasal corticosteroid treatment may signal adrenal suppression.

The patients' blood cortisol levels after cosyntropin are reported before and after the 4 weeks and 6 months of treatment. After four weeks, there was no significant reduction from baseline in the average level of morning cortisol in patients treated with Nasacort AQ (-29.60 plus or minus 42.73 nmol/L; P=0.49), or placebo (-35.50 plus or minus 43.73; P=0.42). Similarly, after 6 months, patients treated with Nasacort AQ, showed no significant reduction from baseline in their average morning cortisol levels (-53.34 plus or minus 40.13 nmol/L; P=0.1900).

About Allergic Rhinitis

Allergic rhinitis is a swelling of the nasal passages, usually accompanied by sneezing, watery nasal discharge and itching of the nose and eyes. This medical condition is caused by an allergic reaction to allergens such as house dust, animal dander, or pollen. On any given day, 10,000 American children miss school because of allergic rhinitis, for a total of 2 million lost school days.

About Nasacort AQ

Nasacort AQ Nasal Spray is indicated for the treatment of the nasal symptoms of seasonal and perennial allergic rhinitis in adults and children 6 years of age and older.

The most commonly reported side effects with Nasacort AQ Nasal Spray were similar to vehicle placebo. In adults and children ages 12 and older, they were: pharyngitis 5.1% vs 3.6%, epistaxis 2.7% vs 0.8%, and increase in cough 2.1% vs 1.5%. In studies including children ages 6 to 11, they were: pharyngitis 7.4% vs 6.4%, increase in cough 7.0% vs 6.4%.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward-looking statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward- looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward- Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2006. Other than as required by applicable law, sanofi- aventis does not undertake any obligation to update or revise any forward- looking information or statements.

Contact: Susan Brooks, (908)-981-6566, Susan.Brooks@sanofi-aventis.com


'/>"/>
SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
2. Nautica Malibu Triathlon Presented by Toyota Raises $718,000 for Childrens Hospital Los Angeles Pediatric Cancer Research
3. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
4. Success of Shape Up Somerville childhood obesity intervention to be presented
5. Survival data presented from phase II study of hormone-resistant prostate cancer patients
6. Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai
7. UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Presented at American Society for Dermatologic Surgery Annual Meeting
8. New Analyses of long-term LIALDA (mesalamine) data presented at ACG
9. Horizons AMI trial data to be presented at TCT 2007
10. AMIHOT II trial data presented at TCT
11. Ellex Announces New Retina Regeneration Therapy to be Presented at the AAO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology: